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Bullet point summary 
 
What is already known 
 Increased circulating homogentisic acid is central to disease pathology in the 
inherited metabolic disease alkaptonuria 
 The Hgd knockout mouse, created in our laboratory, accurately models human 
alkaptonuria 
 
What this study adds 
 Phase I and II biotransformations are recruited in alkaptonuria for detoxification of 
homogentisic acid 
 These data challenge misconceptions that phase I and II metabolism is solely for 
drug clearance 
 
Clinical significance 
 Phase I and II metabolic processes represent new treatment targets in inherited 
metabolic diseases 
 The molecular pathology of AKU extends much further than the known alteration 
to tyrosine metabolism 
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Abstract 
Background and Purpose: alkaptonuria (AKU) is an inherited disorder of tyrosine 
metabolism caused by lack of the enzyme homogentisate 1,2-dioxygenase (HGD). The 
primary biochemical consequence of HGD-deficiency is increased circulating 
homogentisic acid (HGA), which is central to AKU disease pathology. The aim of this 
study was to investigate the wider metabolic consequences of targeted Hgd disruption. 
Experimental Approach: the first metabolomic analysis of the Hgd-/- AKU mouse model 
was performed. Urinary metabolites altered in Hgd-/- were further validated by showing 
that the HGA-lowering drug nitisinone reversed their direction of alteration in AKU  
Key Results: comparison of Hgd-/- (AKU) versus Hgd+/- (heterozygous control) urine 
revealed increases in HGA and a group of 8 previously unreported HGA-derived 
transformation products from phase I and II metabolism. HGA biotransformation products 
HGA-sulfate, HGA-glucuronide, HGA-hydrate and hydroxymethyl-HGA were also 
decreased in urine from both mice and patients with AKU on the HGA-lowering agent 
nitisinone. Hgd knockout also revealed a host of previously unrecognised associations 
between tyrosine, purine and TCA cycle metabolic pathways.  
Conclusion and Implications: AKU is rare, but our findings further what is currently 
understood about tyrosine metabolism more generally, and show for the first time that 
phase I and II detoxification is recruited to prevent accumulation of endogenously-
produced metabolites in inborn errors of metabolism. The data highlight the 
misconception that phase I and II metabolic biotransformations are reserved solely for 
drug clearance; these are ancient mechanisms, which represent new potential treatment 
targets in inherited metabolic diseases.   
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1. Introduction1 
Alkaptonuria (AKU) is a rare disorder of tyrosine metabolism caused by congenital lack 
of the enzyme homogentisate 1,2-dioxygenase HGD (E.C.1.12.11.5) (Zatkova, 2011). 
The biochemical consequence of this deficiency is increased homogentisic acid (HGA) in 
the circulation, the pathognomonic sign of the disease which is central to its 
pathophysiological features (Ranganath et al., 2013). HGA has a high affinity for 
collagenous tissues, where its deposition produces striking pigmentation (Helliwell et al., 
2008), a process called ochronosis. Cartilage of load-bearing joints is particularly 
susceptible to ochronosis. Presence of HGA-derived pigment in these joints alters the 
physicochemical properties of cartilage that support normal transmission of load and 
results in an inevitable and severe early-onset osteoarthropathy (Taylor et al., 2011; 
Chow et al., 2020). 
Metabolomics has emerged as an invaluable approach for studying AKU. Mass 
spectrometric assays have been developed as a targeted metabolomic approach for 
diagnosis and monitoring of AKU (Hughes et al., 2014, 2015a). These assays offer 
precise quantitation of tyrosine pathway metabolites including HGA in serum and urine. 
More recently, a strategy for profiling and chemical identification of hundreds of 
metabolites simultaneously by liquid chromatography quadrupole time-of-flight mass 
spectrometry (LC-QTOF-MS) has been developed (Norman et al., 2019). Application of 
                                               
Abbreviations: AKU, alkaptonuria; HGD, homogentisate 1,2-dioxygenase; HGA, 
homogentisic acid; LC-QTOF-MS, liquid chromatography quadrupole time-of-flight mass 
spectrometry; AMRT, accurate mass / retention time; PCA, principal components 
analysis; RT, retention time; FDR, false-discovery rate; FC, fold change; QC, quality 
control; CV, coefficient of variation; CSF, cerebrospinal fluid; DHMA,  DL-3,4-
dihydroxymandelic acid; VMA, vanillylmandelic acid; CNS, central nervous system. 
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this technique to AKU serum (Davison et al., 2019a) and urine (Norman et al., 2019) 
enabled the discovery of previously unknown metabolite and metabolic pathway 
alterations following treatment with the HGA-lowering agent nitisinone. 
Metabolic profiling has potential in AKU as both a phenotyping and biomarker discovery 
tool. However, to our knowledge, untreated AKU has not been compared with non-AKU 
at the metabolome level before. Here we compared the metabolome of AKU mice, a 
model created by targeted homozygous knockout of the Hgd gene (Hgd-/-), with non-AKU 
heterozygous knockout (Hgd+/-) control mice (Experiment 1). The Hgd-/- mouse 
recapitulates human AKU, with elevated plasma and urine HGA, development of 
ochronosis and its inhibition by nitisinone (Preston et al., 2014; Hughes et al., 2019). We 
then looked to validate any metabolite alterations observed by assessing whether the 
direction of alteration was reversed while on the HGA-lowering drug nitisinone treatment 
in Hgd-/- mice or patients (Experiment 2), and whether the metabolites that were increased 
in Hgd-/- mice were directly derived from HGA via a metabolic flux experiment in which 
mice were injected with stable isotopically-labelled HGA (Experiment 3). Figure 1 
summarizes the overall study design. The overall aim of these experiments was to 
investigate metabolic markers of disease in AKU; identification of novel metabolite 
alterations in a controlled mouse study could elucidate novel disease mechanisms and 
improve current strategies for monitoring the disease process and treatment response. 
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Figure 1. Schematic overview of the overall study design, incorporating 
Experiments 1-3. In Experiment 1, urine was collected from Hgd-/- and Hgd+/- mice and 
profiled by LC-QTOF-MS. Targeted and non-targeted feature extraction was performed 
on the data in parallel and subsequent unpaired t-tests were employed to identify 
differentially abundant chemical entities between Hgd-/- and Hgd+/-. These entities were 
then further investigated in LC-QTOF-MS data from two additional datasets; a previously 
published study examining the effect of nitisinone on the urine metabolome of Hgd-/- 
BALB/c mice and patients with AKU (Norman et al., 2019) (Experiment 2) and a plasma 
flux analysis using a 13C6 labelled HGA tracer (Experiment 3). 
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2. Methods 
2.1 Experimental Design 
The study comprised three experimental components (Figure 1). In Experiment 1 we 
employed non-targeted LC-QTOF-MS profiling to characterize the metabolome of a 
mouse model of AKU by targeted homozygous Hgd knockout (Hgd-/-), with non-AKU 
heterozygous knockout (Hgd+/-) mice as controls (Experiment 1). We then looked to 
validate the metabolite alterations observed by assessing whether the direction of 
alteration was reversed following nitisinone treatment in Hgd-/- mice or patients with AKU 
(Experiment 2), and additionally whether the metabolites that were increased in Hgd-/- 
mice were directly derived from the increased HGA via a metabolic flux experiment in 
which mice were injected with stable isotopically-labelled HGA (Experiment 3). All mice 
were housed in the University of Liverpool’s Biomedical Services Unit under pathogen-
free conditions, in cages of up to 5 mice, with 12-hr light/dark cycle, and food and water 
available ad libitum. Mice were drug/test naïve at baseline in each experiment. 
2.2 Materials 
Deionised water was purified in-house by DIRECT-Q 3UV water purification system 
(Millipore, Watford, UK). Methanol, acetonitrile, isopropanol (Sigma-Aldrich, Poole, UK), 
formic acid (Biosolve, Valkenswaard, Netherlands) and ammonium formate (Fisher 
Scientific, Schwerte, Germany) were LC/MS grade. 13C6 labelled HGA for metabolic flux 
analysis was purchased from Toronto Research Chemicals (Toronto, Canada). 
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2.3 Urine sample collection and preparation for metabolic profiling (Experiment 
1) 
For metabolomic analysis of the targeted Hgd knockout phenotype (Hughes et al., 2019), 
urine was collected from 15 Hgd-/- (mean age ±SD 12.8±0.1 weeks) and 14 Hgd+/- (mean 
age 11.6±0.3) weeks) male C57BL/6 mice. All urine was taken on a single-collection basis 
and stored at -80°C.  
Pooled samples were created in each profiling experiment for quality control (QC) 
purposes. For Hgd-/- and Hgd+/- groups a separate representative pool was created by 
pooling 20µL of each individual urine sample. An overall pool was also created for each 
experiment by pooling equal proportions of the above group pools. Analysis of individual 
and pooled samples was performed following dilution of 1:9 urine:deionised water as 
previously described (Norman et al., 2019). 
2.4 Investigating the effect of nitisinone on metabolites showing alteration in 
Hgd-/- mice and patients with AKU (Experiment 2) 
The effect of nitisinone treatment on urinary metabolites altered in Hgd-/- mice (Figure 1, 
Experiment 1) was studied in the data from a previous profiling experiment described by 
Norman et al. (Norman et al., 2019). These data were from urine from 18 BALB/c Hgd-/- 
mice (mean age 27±12 weeks, 9 female, 9 male) with Hgd disruption by ENU 
mutagenesis (Preston et al., 2014) and from 25 patients attending the UK National 
Alkaptonuria Centre (NAC; mean age 51±15 years, 13 female, 12 male). The disease 
phenotypes of Hgd-/- mice from targeted knockout and ENU mutagenesis models are 
identical (Hughes et al., 2019). Mouse urine was collected at baseline then after 1 week 
on nitisinone, administered in drinking water at 4mg/L, supplied ad libitum. Human urine 
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was collected at baseline then after 24 months on nitisinone (2mg daily). These datasets 
were acquired under identical LC-QTOF-MS analytical conditions to those employed in 
the present study. 
2.5 Design of in vivo metabolic flux experiment and sample collection 
(Experiment 3) 
Eight C57BL/6 mice were studied in the HGA metabolic flux experiment; 4 Hgd-/- (mean 
age 56±2.3 weeks, 1 female, 3 male) and 4 Hgd+/- (mean age 58±0 weeks, 4 female). A 
1.96mg/mL 13C6 HGA tracer solution was prepared in sterile saline and injected into the 
tail vein. Injection volume was adjusted for each mouse to achieve a final blood 
concentration of 1mmol/L, assuming a total blood volume of 75mL/kg (Laboratory Animal 
Science Association, 1998). Venous tail bleed samples were then taken at 2, 5, 10, 20, 
40 and 60 min post-injection, keeping sampling volumes within LASA guidelines 
(Laboratory Animal Science Association, 1998). Mice were kept anaesthetised with 
isoflurane throughout the experiment. Blood was collected into Microvette 300µL lithium 
heparin capillary tubes (Sarstedt, Nümbrecht, Germany) and centrifuged at 1500x g for 
10 min. Plasma supernatant was removed and stored at -80°C prior to analysis. Individual 
plasma samples were analysed following 1:9 plasma:deionised water. 
2.6 LC-QTOF-MS analytical conditions 
Analysis of plasma and urine was performed on an Agilent 1290 Infinity HPLC coupled to 
an Agilent 6550 QTOF-MS (Agilent). Data acquisition parameters are detailed in 
Appendix 1. 
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2.7 Design of LC-QTOF-MS profiling analyses 
Samples from Experiments 1 (Hgd-/- vs Hgd+/-) and 3 (13C6 HGA metabolic flux analysis) 
were analysed in separate batches, each comprising negative then positive polarity. The 
analytical sequence of each profiling batch was designed according to published 
guidance (Vorkas et al., 2015) and following the procedure described previously by 
Norman et al. (Norman et al., 2019). 
2.8 Data processing and statistical analyses 
Mining of metabolite features in raw data was performed using two parallel approaches 
(Figure 1, Experiment 1). A targeted approach was used to extract signals matching a 
466-compound AMRT database previously generated in our laboratory from IROA 
Technology MS metabolite library of standards, accessible via 
https://doi.org/10.6084/m9.figshare.c.4378235.v2 (Norman et al., 2019), or a compound 
database comprising accurate masses of additional compounds with potential relevance 
to AKU. A complementary non-targeted approach was used to extract unknown chemical 
entities. 
2.8.1 Targeted feature extraction 
Targeted feature extraction was performed in Profinder (build 08.00, Agilent) using the 
chemical formulae of compounds from the AMRT database described above. Extraction 
parameters were accurate mass match window ±10ppm and retention time (RT) window 
±0.3 min. Allowed ion species were: H+, Na+, and NH4+ in positive polarity, and H- and 
CHO2- in negative polarity. Charge state range was 1-2, and dimers were allowed. ‘Find 
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by formula’ filters were: score >60 in at least 60% of samples in at least one sample group 
(samples were grouped by Hgd-/- or Hgd+/- and pre- or on nitisinone). 
Eighty-five additional metabolites of potential interest in AKU or from wider tyrosine 
metabolism were appended to the database for targeted extraction. Forty-three were from 
the following pathway databases available from Pathways to PCDL (build 07.00, Agilent): 
‘citrate degradation’, ‘noradrenaline and adrenaline degradation’ and ‘superpathway of 
phenylalanine, tyrosine and tryptophan biosynthesis’ (Appendix 2). Six metabolites were 
added as they were predicted to show potential alteration in Hgd-/- due to association with 
tyrosine conjugation (acetyl-L-tyrosine, and γ-glutamyl-tyrosine) based on a previous 
publication (Norman et al., 2019) or association with ochronotic pigment derived from 
HGA (2,5-dihydroxybenzaldehyde, di-dehydro-homogentisic acid, hipposudoric acid and 
norhipposudoric acid). Thirty-six metabolites were from a list of potential 
biotransformation products directly derived from HGA and compiled using the 
Biotransformation Mass Defects application (Agilent; Appendix 3). This tool provides a list 
of potential metabolic biotransformation products covering both phase I (n=19) and II 
(n=17) metabolism for a given compound based on empirical formula. The data were 
mined for these additional metabolites with putative identification by accurate mass 
(±5ppm) only. 
2.8.2 Non-targeted feature extraction 
Non-targeted extraction was performed by recursive feature extraction in Profinder (build 
08.00). Extraction parameters are detailed in Appendix 4. 
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2.8.3 Isotopologue feature extraction on data from 13C6 HGA metabolic flux analysis 
Data from Experiment 3 (Figure 1) were mined using batch isotopologue extraction in 
Profinder (build 08.00). Here, compounds that showed significant differences between 
Hgd-/- and Hgd+/- mice (Experiment 1) were investigated for potential association with the 
13C6 HGA tracer by examining the relative abundances of their M+0 to M+6 isotopologues. 
Extraction was performed with accurate mass and RT match windows of ±5ppm and ±0.3 
min respectively against an AMRT database consisting only of these compound targets. 
2.8.4 Data QC and statistical analyses 
First, initial QC was performed on all datasets in Profinder by manual curation of the 
dataset to remove visually low quality peaks and to correct integration issues across the 
dataset where appropriate. 
Urine profiling datasets were then exported from Profinder as .csv files and imported into 
Mass Profiler Professional (build 14.5, Agilent) for additional QC and subsequent 
statistical analyses. First, creatinine peak area from this analysis creatinine was used as 
an external scalar for each mouse sample to correct for differences in urine concentration, 
as described previously (Norman et al., 2019). Additional QC was performed using data 
from pooled samples, which were interspersed throughout each analytical sequence. 
Entities were retained if a) observed in 100% of replicate injections for at least one sample 
group pool, and b) peak area coefficient of variation (CV) remained <25% across replicate 
injections for each sample group pool. Statistically significant entities were then identified 
in each dataset by t-tests; unpaired t-tests for Hgd-/- vs Hgd+/- comparisons, and paired t-
tests for pre- vs on nitisinone comparisons. Multiple testing correction was performed 
using Benjamini-Hochberg false discovery rate (FDR) adjustment. FC’s were log2-
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transformed and based on peak area. FC cut-off was not applied for entities with FDR-
adjusted p<0.05 however, in order to retain entities that showed consistent although 
relatively low magnitude abundance differences between comparison groups. Principal 
Components Analysis (PCA) was performed on each filtered dataset using four-
component models. 
The results from isotopologue extraction on plasma 13C6 HGA metabolic flux data were 
reviewed visually in Profinder for clear evidence of an isotope label likely to be derived 
from HGA. This data review was performed for compound matches individually, 
considering the predicted number of 13C atoms derived from the HGA tracer based on the 
compound’s chemical structure. 
2.9 Study approval 
All animal work was carried out in accordance with UK Home Office Guidelines under the 
Animals (Scientific Procedures) Act, 1986. 
Metabolomic analyses on patient samples was approved by the Royal Liverpool and 
Broadgreen University Hospital Trust’s Audit Committee (audit no. ACO3836) and was 
part of the diagnostic service to patients being seen at the NAC. 
3. Results 
PCA showed clear separation in principal component 1 between the urine profiles of Hgd-
/- and Hgd+/- mice from targeted (Figures 2A & 2B) and non-targeted feature extraction. 
Results from targeted and non-targeted extraction are presented separately in the 
following sections (number of entities obtained in each extraction method summarised in 
Appendix 5). Data from all animals in each experiment were included in the analysis. 
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3.1 Targeted feature extraction 
Targeted feature extraction was performed to search for metabolites based on AMRT 
(accurate mass ±10ppm, RT ±0.3 min) or accurate mass (±5ppm) alone. 27/250 and 
15/243 metabolites showed abundance differences (FDR-adjusted p<0.05) between Hgd-
/- and Hgd+/- in negative and positive polarity, respectively. Table 1 shows the altered 
metabolites ranked by FC. PCA loadings plots (Figures 2C & 2D) and volcano plots 
(Figures 2E & 2F) show that the greatest differences between Hgd-/- and Hgd+/- urine were 
in metabolites associated with HGA in negative and positive polarity. HGA and 8 predicted 
HGA biotransformation products were markedly elevated in Hgd-/-. Interestingly, HGA-
sulfate (FC=9.3, p<0.0001) showed a greater FC increase than HGA (FC=7.9, p<0.0001). 
Six other HGA products were increased with FC >1.5 and p<0.0001: HGA-glucuronide, 
HGA-hydroxyl-sulfate, HGA-N-acetylcysteine, HGA-hydrate, HGA-(de-alkene)-epoxide 
and HGA-(de-ethyl)-carboxylate. Acetyl-HGA was elevated in Hgd-/- (FC=2.3, p<0.0001), 
but did not pass QC filtering by CV <25% across replicate injections of pooled QC 
samples; a decrease in signal across the run indicated a stability issue (despite the auto-
sampler being maintained at 4°C). 
Excluding HGA, 26 significantly altered entities, were AMRT-matched with compounds 
from the 466-compound library developed in-house. The most significantly altered 
(p<0.05 and log2 FC>1.5) of these were:  thymidine-5’-diphospho-alpha-D-glucose, DL-
3,4-dihydroxymandelic acid, 2-aminophenol, p-hydroxyphenylacetic acid (increased in 
Hgd-/-), malic acid, isocitrate and inosine 5’-monophosphate (decreased in Hgd-/-). 
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Figure 2. Clear differences between the urine metabolomes of Hgd-/- and Hgd+/- 
mice. A-D: PCA on data from targeted feature extraction, with PCA plots showing 
separation between Hgd-/- and Hgd+/- mice by component 1 in A, negative, and B, positive 
ionisation polarities. Lower plots show the corresponding PCA loadings of metabolites on 
components 1 and 2 in C, negative, and D, positive polarity. E-F: volcano plots illustrating 
selection of statistically significant urinary chemical entities between Hgd-/- and Hgd+/- 
mice based on p-value and fold change. E, negative polarity; F, positive polarity. Entities 
with p<0.05 (Benjamini-Hochberg FDR adjusted) and log2 fold change >1.5 are labelled, 
with red and blue indicating increased and decreased abundance, respectively, in Hgd-/-. 
Turquoise indicates adjusted p<0.05 but log2 fold change <1.5. 
Bold text indicates that the increase observed in Hgd-/- was confirmed in mouse plasma 
following injection with 13C6 HGA tracer. 
* Compound not previously reported in the literature. 
 
3.2 Non-targeted feature extraction 
Non-targeted feature extraction yielded 359 and 213 chemical entities post-QC in 
negative and positive polarity respectively; mass range = 54-3108 Da and RT range = 
1.1-11.5 min. Comparison of Hgd-/- and Hgd+/- revealed entities with clear abundance 
differences (p<0.05, log2 FC>1.5); 9 in negative polarity (6 increased in Hgd-/-, 3 
decreased in Hgd-/-) and 2 in positive polarity (both increased in Hgd-/-). The mass range 
of these significant entities was 242-507 Da, and RT range was 1.7-9.6 min (Table 1). 
Candidates compound matches were obtained for two of these entities based on accurate 
mass match (<10ppm) with the MassHunter METLIN metabolite PCD/PCDL accurate 
mass database (build 07.00; accessed through Agilent PCDL Manager build 8.00); 2-
amino-6-(benzylthio)purine (increased in Hgd-/-) and vanilyl pyruvic acid (decreased in 
Hgd-/-). 
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Table 1. Summary of identified metabolites or chemical entities showing altered abundance in Hgd-/- mice. Direction 
of alteration and log2 fold change is indicated in Hgd-/- (relative to Hgd+/-) and following nitisinone treatment in Hgd-/- (paired 
data; on nitisinone relative to pre-nitisinone). P-values are false discovery rate adjusted. Where entities were significantly 
different in positive and negative polarity, the result with the lowest fold change is provided.  
 
* Compound identification by matched accurate mass (±10ppm) and RT (±0.3mins) (otherwise, identification by accurate mass ±5ppm 
only). 
† Entity obtained from non-targeted data mining with putative identification by accurate mass (±10ppm) only 
‡ Note acetyl-HGA failed QC filtering (CV >25% across replicate injections of QC pooled samples; due to suspected compound stability 
issue over analysis period). 
Compound Neutral mass RT (min) 
Direction of 
alteration in Hgd-/- 
Log2 fold 
change 
p-value 
HGA-sulfate 247.9996 2.6 ↑ 9.3 <0.0001 
HGA* 168.0434 3.4 ↑ 7.9 <0.0001 
HGA-glucuronide 344.075 2.4 ↑ 5 <0.0001 
HGA-hydroxyl-sulfate 263.9931 2.8 ↑ 4.2 <0.0001 
HGA-N-acetylcysteine 329.057 4.5 ↑ 4 <0.0001 
Thymidine-5’-diphospho-alpha-D-
glucose* 
564.0758 2.4 ↑ 3.3 <0.0001 
Unknown 268.9662 2.6 ↑ 2.8 <0.0001 
Unknown 367.0289 3.4 ↑ 2.6 <0.0001 
DL-3,4-Dihydroxymandelic acid* 184.037 1.9 ↑ 2.5 <0.0001 
HGA-hydrate 186.053 3.4 ↑ 2.4 <0.0001 
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Unknown 507.141 3.4 ↑ 2.4 <0.0001 
Acetyl-HGA‡ 210.053 6.2 ↑ 2.3 <0.0001 
Unknown 287.9939 6.0 ↑ 2.3 0.025 
HGA-(de-alkene)-epoxide 184.0369 1.8 ↑ 2.2 <0.0001 
2-Amino-6-(benzylthio)purine† 257.0758 3.5 ↑ 2.2 <0.0001 
Unknown 257.0391 3.4 ↑ 2.0 <0.0001 
HGA-(de-ethyl)-carboxylate 184.0017 3.4 ↑ 1.8 <0.0001 
2-Aminophenol* 109.0534 1.9 ↑ 1.7 0.035 
Unknown 294.0949 3.6 ↑ 1.7 <0.001 
p-Hydroxyphenylacetic acid* 152.0478 5.5 ↑ 1.6 <0.0001 
Unknown 361.0827 1.7 ↑ 1.5 <0.001 
3-Dehydroshikimic acid* 172.0373 1.8 ↑ 1.2 <0.01 
Hydroxymethyl-HGA 198.0526 4.8 ↑ 1.1 <0.0001 
Aceturic acid* 117.0426 1.7 ↑ 0.94 <0.01 
Nicotinic acid* 123.032 1.8 ↑ 0.8 0.015 
4-Hydroxybenzaldehyde* 122.0368 5.6 ↑ 0.8 0.014 
Vanillylmandelic acid* 198.0528 3.3 ↑ 0.75 <0.01 
N-Acetyl-DL-serine* 147.0532 1.6 ↑ 0.66 <0.01 
N-Acetylaspartate* 175.0481 1.8 ↑ 0.64 0.018 
Xanthosine* 284.0762 3.4 ↑ 0.53 0.028 
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N-Alpha-acetyl-l-asparagine* 174.0641 1.6 ↑ 0.52 <0.01 
N-Acetyl-L-phenylalanine* 207.0895 6.8 ↑ 0.52 0.049 
3,5-Cyclic-AMP* 329.0525 3.4 ↑ 0.44 0.012 
Malic acid* 134.0211 1.5 ↓ 2.6 <0.001 
Isocitrate* 192.0278 1.7 ↓ 2.1 <0.001 
Vanilyl pyruvic acid† 256.0582 5.0 ↓ 2.1 <0.001 
Inosine 5’-monophosphate* 348.05 1.8 ↓ 2 <0.001 
Unknown 242.0427 4.0 ↓ 1.7 <0.0001 
Unknown 362.086 9.6 ↓ 1.6 <0.01 
Glucuronolactone* 176.0321 1.6 ↓ 1.4 <0.01 
Methylmalonic acid* 118.0266 2.0 ↓ 1.1 <0.0001 
Monomethyl-glutaric acid* 146.0579 5.1 ↓ 0.82 0.029 
N-Acetyl-L-glutamic acid* 189.0637 2.1 ↓ 0.76 <0.01 
Citramalic acid* 148.039 2.6 ↓ 0.7 <0.0001 
L-anserine* 240.1222 1.3 ↓ 0.59 <0.01 
2,3-Cyclic AMP* 329.0525 2.7 ↓ 0.58 <0.01 
O-Succinyl-L-homoserine* 219.0743 2.0 ↓ 0.35 0.019 
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3.3 The effect of nitisinone treatment on chemical entities altered in Hgd-/- mice 
To investigate the effect of nitisinone treatment on the entities shown to be altered here 
in Hgd-/-, they were searched in the data from previous mouse and human urine profiling 
experiments (Figure 1, Experiment 2). These data were acquired from Hgd-/- mice at 
baseline then after 1 week on nitisinone, and from patients with AKU at baseline then 
after 24 months on nitisinone (Norman et al., 2019).  
Eight entities from targeted feature extraction that were altered in Hgd-/- vs Hgd+/- mice 
were significantly altered in the opposite direction in urine from both Hgd-/- mice and 
patients with AKU on nitisinone (based on peak area pre- vs on nitisinone, Benjamini-
Hochberg FDR-adjusted p<0.05; Table 2); 7 decreased, and 1 increased. The 7 
decreased metabolites were HGA, the HGA biotransformation products HGA-sulfate, 
HGA-glucuronide, HGA-hydrate and hydroxymethyl-HGA, and also xanthosine and 3,5-
cyclic-AMP. The increased metabolite was monomethyl-glutaric acid. Interestingly, p-
hydroxyphenylacetic acid and 4-hydroxybenzaldehyde were increased both in Hgd-/- vs 
Hgd+/- and also on nitisinone in Hgd-/- mice and patients. 
Nineteen entities that were altered in Hgd-/- vs Hgd+/- mice were significantly altered in the 
opposite direction on nitisinone in urine from either Hgd-/- mice (n=14; 9 decreased, 5 
increased on nitisinone) or patients (n=5; 4 decreased, 1 increased on nitisinone) only 
(Table 2). These compounds comprised the remaining HGA biotransformation products, 
except HGA-(de-ethyl)-carboxylate, which were all decreased on nitisinone. On 
nitisinone, acetyl-HGA was decreased in patients only, and HGA-hydroxyl-sulfate, HGA-
N-acetylcysteine and HGA-(de-alkene)-epoxide were decreased in mice only. 
 
.CC-BY 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.04.16.044347doi: bioRxiv preprint 
22 
 
Table 2. The effect of nitisinone treatment in Hgd-/- mice and patients with AKU on the abundance of urinary 
chemical entities altered in Hgd-/- vs Hgd+/- mice. The entities that showed differences between Hgd-/- vs Hgd+/- mice 
(Table 1) were examined in two additional datasets. Paired t-tests were employed to compare the abundances at baseline 
versus 1 week on nitisinone (4mg/L, in drinking water) for Hgd-/- mice and 24 months on 2mg daily nitisinone for patients 
with AKU. Only entities with false discovery rate adjusted p<0.05 pre- vs on nitisinone in mouse or human are displayed. 
Direction of alteration and log2 fold change are indicated. Where entities were significantly different in positive and negative 
polarity, the result with the lowest fold change is provided. Note: no fold change indicated for hydroxymethyl-HGA in humans, 
as this compound was not detected for any patient on nitisinone. 
 
* Compound identification by matched accurate mass (±10ppm) and RT (±0.3mins) (otherwise, identification by accurate mass ±5ppm 
only). 
† Entity obtained from non-targeted data mining with putative 
ND: compound not detected at baseline or on nitisinone. 
Compound Neutral mass RT (min) Hgd-/- mouse urine  Human urine  
 
 
  
Alteration 1 
week on 
nitisinone 
Log2 fold 
change 
 
p-value  Alteration 24 
months on 
nitisinone 
Log2 fold 
change 
 
p-value 
HGA-glucuronide 344.075 2.4 ↓ 2.4 <0.0001  ↓ 2.4 
<0.000
1 
HGA-(de-alkene)-epoxide 184.0369 1.8 ↓ 2.3 <0.0001  -   
HGA-hydroxyl-sulfate 263.9931 2.8 ↓ 2.3 <0.0001  ND   
2-Aminophenol* 109.0534 1.9 ↓ 2.2 <0.001  -   
HGA-sulfate  247.9996 2.6 ↓ 2.2 <0.0001  ↓ 3.5 
<0.000
1 
Unknown 268.9662 2.6 ↓ 2.0 <0.0001  ND   
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DL-3,4-Dihydroxymandelic 
acid* 
184.037 1.9 ↓ 1.6 <0.0001  -   
HGA* 168.0434 3.4 ↓ 1.6 <0.0001  ↓ 3.4 
<0.000
1 
Hydroxymethyl-HGA  198.0526 4.8 ↓ 1.1 <0.001  ↓ - 
<0.000
1 
Aceturic acid* 117.0426 1.7 ↓ 1.1 <0.0001  -   
Xanthosine* 284.0762 3.4 ↓ 1 <0.0001  ↓ 2.2 
<0.000
1 
HGA-hydrate 186.053 3.4 ↓ 0.8 <0.0001  ↓ 3.8 
<0.000
1 
HGA-N-acetylcysteine  329.057 4.5 ↓ 0.7 <0.001  -   
N-Acetyl-DL-serine* 147.0532 1.6 ↓ 0.5 0.031  -   
Nicotinic acid* 123.032 1.8 ↓ 0.4 0.014  -   
3,5-Cyclic-AMP* 329.0525 3.4 ↓ 0.3 0.041  ↓ 2 
<0.000
1 
Acetyl-HGA 210.053 6.2 -    ↓ 2.7 
<0.000
1 
Vanillylmandelic acid* 198.0528 3.3 -    ↓ 1 <0.01 
2-Amino-6-
(benzylthio)purine† 
257.0758 3.5 -   
 
↓ 0.9 0.035 
N-Alpha-acetyl-l-
asparagine* 
174.0641 1.6 -    ↓ 0.4 <0.01 
Malic acid* 134.0211 1.5 ND    ↑ 0.8 0.028 
p-Hydroxyphenylacetic 
acid* 
152.0478 5.5 ↑ 3.3 <0.0001  ↑ 3 
<0.000
1 
4-Hydroxybenzaldehyde* 122.0368 5.6 ↑ 2.32 <0.0001  ↑ 6.6 
<0.000
1 
N-Acetyl-L-phenylalanine* 207.0895 6.8 ↑ 1.8 <0.0001  -   
Unknown 294.0949 3.6 ↑ 1.8 <0.0001  ↓ 0.6 <0.001 
.CC-BY 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.04.16.044347doi: bioRxiv preprint 
24 
 
Unknown 362.086 9.6 ↑ 1.4 <0.0001  ND   
Isocitrate* 192.0278 1.7 ↑ 1.2 <0.01  -   
N-Acetylaspartate* 175.0481 1.8 ↑ 0.9 0.023  -   
Citramalic acid* 148.039 2.6 ↑ 0.8 0.023  -   
N-Acetyl-L-glutamic acid* 189.064 2.1 ↑ 0.8 <0.0001  -   
Monomethyl-glutaric acid* 146.0579 5.1 ↑ 0.4 <0.01  ↑ 1.7 0.041 
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3.4 Confirmation of HGA biotransformation products by 13C6 HGA metabolic flux 
analysis (Experiment 3) 
Data from isotopologue extraction were compared between plasma collected from the 
same mice across the time intervals available (2-60 min). The M+6 isotopologue was of 
particular interest as mice were injected with 13C6-labelled HGA (although M+ 0-5 
isotopologues were also considered for compounds where the labelled 13C carbons of the 
benzene ring could potentially be removed through metabolism of HGA).  
A clear M+6 peak for HGA was observed over the sampling time course in plasma from 
Hgd-/- and Hgd+/- mice, although the signal decreased from 10-20 min post-injection 
(Figure 3). As indicated in Figure 2 (compounds in bold text), 2 HGA biotransformation 
products that were increased in Hgd-/- urine were observed with clear M+6 peaks over the 
time course; HGA-glucuronide and HGA-sulfate. These data confirm that the compounds 
are derived from HGA. HGA-sulfate showed a similar time course profile to HGA. For this 
compound the native M+0 isotopologues were also absent from Hgd+/- plasma at all time 
points, in contrast to the M+6 isotopologue whose profile appeared to closely follow that 
of the HGA M+6 peak over the time course in both Hgd-/- and Hgd+/- (Figure 3). For HGA-
glucuronide, the native M+0 isotopologue was also absent from Hgd+/- plasma, but the 
M+6 isotopologue was only observed in Hgd-/- (Figure 3), indicating that glucuronidation 
of the HGA tracer was evident only for Hgd-/- mice. 
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Figure 3. Isotopologue extraction results on plasma from the in vivo metabolic flux experiment using injected 13C6-
labelled homogentisic acid (HGA). Data shown are from Hgd-/- and Hgd+/- samples taken at intervals of 2, 5, 10, 20, 40 
and 60 (when possible) min after injection. Extracted ion chromatograms (EIC’s) represent the M+0 (native compound) and 
M+6 (13C6-labelled form) isotopologue signals for HGA, HGA-sulfate and HGA-glucuronide. EIC’s show clear M+6 peaks 
for these compounds following injection (but only from Hgd-/- mice for HGA-glucuronide), confirming that they are derived 
from the labelled HGA.
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4. Discussion 
The data reported here from the first metabolome-wide comparison of non-treated AKU 
vs non-AKU (Hgd-/- vs Hgd+/- mice; Experiment 1) show that the biochemical 
consequences of HGD-deficiency are wider-reaching than previously recognised and 
extend beyond tyrosine metabolism. The data further reveal for the first time that phase I 
and II metabolic processes are recruited for detoxification of the markedly increased HGA. 
The observation of a reversed direction of alteration for a number of these urinary 
metabolites following nitisinone treatment in mice and patients (Experiment 2) indicates 
that these changes observed in the mouse model of AKU apply to the human disease. 
4.1 HGA biotransformation products from phases I and II metabolism 
The clearest differences between the urine metabolomes of Hgd-/- versus Hgd+/- mice 
were associated with HGA; HGA and 8 previously unreported HGA-derived 
biotransformation products were increased in Hgd-/-. Figure 4 shows the predicted 
structures for 7 of these novel compounds and the enzyme families responsible for their 
production. Reversed alteration (decreases) in HGA-sulfate, HGA-glucuronide, HGA-
hydrate, acetyl-HGA and hydroxymethyl-HGA for patients on nitisinone (Experiment 2) 
adds validation and indicates that these HGA biotransformation processes are recruited 
in human AKU.  
Observation of 13C6-labelled forms of HGA-glucuronide and HGA-sulfate in plasma 
following 13C6-HGA injection in mice (Experiment 3) confirmed that these products are 
derived from HGA. 13C6-HGA-sulfate was observed in Hgd-/- and Hgd+/- mice, following the 
profile of the 13C6-HGA across the sampling time course. Interestingly, 13C6-HGA-
glucuronide was only observed in Hgd-/-, suggesting prior upregulation of 
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glucuronyltransferase activity for HGA clearance in AKU. HGA-glucuronide (FC=5), HGA-
sulfate (FC=9.3) and HGA (FC=7.9) showed the greatest increases in Hgd-/- versus Hgd+/-
.  
Figure 4. Predicted structures of newly-identified HGA clearance products 
resulting from phase I and II metabolism. The proposed sites for 
metabolism/conjugation were those with the greatest probability from in silico prediction 
tools Stardrop (Optibrium, Cambridge, UK) and Reacting Atom (Way2Drug, Moscow, 
Russia), for phase I and II biotransformations respectively. Note: HGA positions labelled 
7 and 11 have equal probability for sulfation (deltaP = 0.8). 
 
To our knowledge, these are the first data on HGA metabolism outside of its conversion 
to maleylacetoacetic acid in the traditional tyrosine degradation pathway. Phase I and II 
pathways are traditionally considered as routes for drug metabolism with their enzymes 
primarily located in the liver; as with the enzymes of the tyrosine pathway (Williams et al., 
.CC-BY 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.04.16.044347doi: bioRxiv preprint 
29 
 
2012). Phase I metabolism comprises reactions to introduce reactive or polar groups to 
substrates and includes hydroxylation, oxidation, reduction and hydrolysis. Phase II 
metabolism involves conjugation reactions to form glucuronide, glutathione, mercapturic 
acid, amino acid, methyl and acetyl conjugates (Williams, 1971; Wolff and Jordan, 1987). 
Phase I and II reactions can also occur sequentially; here the compounds hydroxymethyl-
HGA and HGA-hydroxylsulfate were formed by hydroxylation with subsequent 
methylation (hydroxymethyl-HGA) or sulfation (HGA-hydroxylsulfate). Not all phase I and 
II biotransformations are adaptive clearance mechanisms. HGA-(de-alkene)-epoxide is a 
product of HGA bioactivation; epoxide metabolites are generally reactive, electrophilic 
compounds that require further enzymatically-mediated detoxification (Obach and 
Kalgutkar, 2010; Hughes et al., 2015b). It is also worth noting the potential HGA 
biotransformation products that were not detected in Hgd-/- in this study (see Appendix 3 
for the full list of potential HGA-derived products predicted in silico). A particularly notable 
example is the absence of a glycine conjugate of HGA, as glycine conjugation is a known 
detoxification mechanism of a number of other aromatic acids (Knights et al., 2007; 
Knights and Miners, 2012). 
The magnitude of these alterations is of potential clinical importance in AKU as they reveal 
for the first time the specific metabolic processes that are major detoxification 
mechanisms to render HGA chemically inert. HGA is the primary toxic agent in AKU; its 
oxidation produces ochronotic pigment, which becomes bound within the extracellular 
matrix of collagenous tissues. The benzoquinone intermediates in ochronotic pigment 
formation are highly reactive species capable of inducing oxidative changes to proteins 
and lipids (Hegedus and Nayak, 1994; Braconi et al., 2015). These oxidative alterations 
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are likely to self-perpetuate osteoarthropathy associated with ochronosis and could 
account for cases of acute fatal metabolic consequences reported in the literature 
(Davison et al., 2016). Identification of the specific enzymes that catalyse these HGA 
biotransformations could inform future AKU therapeutic interventions aimed at enhancing 
HGA degradation. Glucuronidation, for example, is quantitatively one of the most 
important phase II biotransformation reactions, carried out by 15 UPD-
glucuronosyltransferase enzymes in humans (Burchell et al., 1991; Tukey and 
Strassburg, 2000). A number of agents, including naturally occurring dietary compounds, 
are known to be potent inducers of UPD-glucuronosyltransferases and other phase II 
enzymes (Talalay et al., 1988; Prestera et al., 1993; Fahey and Talalay, 1999); our data 
show that such agents have potential use in diseases caused by toxic metabolite 
accumulation, including inborn errors of metabolism.  
4.2 Associated alteration to tyrosine, purine and TCA cycle metabolism in AKU 
This study showed for the first time that in untreated AKU there is alteration to tyrosine, 
purine and TCA cycle metabolites (Figure 5). These data add to a growing body of 
evidence from metabolomic studies that perturbations in tyrosine, purine and energy 
metabolism are linked in numerous diseases including Alzheimer’s (Kaddurah-Daouk et 
al., 2011, 2013), depression (Weng et al., 2015) and diabetic nephropathy (Men et al., 
2017).  
Previous metabolomic studies in AKU have focused solely on the impact of nitisinone on 
the metabolome (Davison et al., 2018a, 2018b, 2019a, 2019b; Norman et al., 2019). 
Nitisinone reversibly inhibits hydroxyphenylpyruvic acid dioxygenase (HPPD; E.C. 
1.13.11.27), the enzyme that produces HGA, and it is currently the most effective 
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treatment for AKU. Nitisinone reduces plasma and urine HGA concentrations 
(Phornphutkul et al., 2002; Introne et al., 2011; Olsson et al., 2015; Ranganath et al., 
2016; Milan et al., 2017), completely arrests ochronosis in AKU mice (Preston et al., 2014; 
Keenan et al., 2015) and more recently was shown to slow progression of morbidity in 
patients attending the UK NAC (2mg nitisinone daily) (Ranganath et al., 2018). We 
showed previously in serum and urine that nitisinone induced an extended network of 
metabolic alteration within tyrosine and neighbouring pathways, including tryptophan, 
purine and TCA cycle (Davison et al., 2019a; Norman et al., 2019). This alteration is a 
concern in AKU, and particularly in hereditary tyrosinaemia type-1, another inherited 
disorder of tyrosine metabolism, in which nitisinone treatment is essential from early 
infancy (McKiernan et al., 2015). 
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Figure 5. Summary of metabolites altered in Hgd-/- mouse urine grouped by their 
associated pathways. Left: the tyrosine degradation pathway showing lack of the 
enzyme HGD in AKU and the consequential increase in HGA. Right (boxes): observed 
metabolite alterations grouped by pathway; red and blue indicate increased and 
decreased abundance respectively. Tyrosine metabolites including HGA, and HGA 
clearance products from phase I and II metabolism were elevated. Metabolites associated 
with the TCA cycle were decreased. A combination of increased and decreased 
abundance was observed for purine pathway metabolites. 
 
4.2.1 Alteration to tyrosine metabolism 
The increases in tyrosine metabolites, excluding HGA, were unexpected in untreated 
AKU. Increases in metabolites upstream of HPPD previously reported in nitisinone-
treated AKU were thought to be a direct consequence of the inhibition of HPPD by 
nitisinone and the consequential hypertyrosinaemia (Davison et al., 2019a; Norman et 
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al., 2019). For the first time, the present data show that targeted Hgd disruption in Hgd-/- 
mice induces metabolic changes upstream of HGA, despite no increase in tyrosine, HPPA 
or HPLA. The altered tyrosine metabolites were increased 3-dehydroshikimic acid, 3,4-
dihydroxymandelic acid (DHMA) ,4-hydroxybenzaldehyde, hydroxyphenylacetic acid and 
vanillymandelic acid (VMA).  
DHMA and VMA are catecholamine metabolites derived from noradrenaline. 
Noradrenaline is derived from tyrosine, via L-DOPA and dopamine, and metabolised to 
DHMA (via 3,4-dihydroxymandelaldehyde) then to VMA, or alternatively to adrenaline or 
normetadrenaline. It is surprising that these increases were observed in untreated AKU 
despite no increase in tyrosine. However, increased DHMA and VMA indicate increased 
metabolism of noradrenaline via 3,4-dihydroxymandelaldehyde as opposed to adrenaline 
or normetadrenaline in untreated AKU, which is supported by a previous observation 
of  decreased urinary normetadrenaline in patients with AKU taking nitisinone (Davison 
et al., 2018a).  
The cause of these unexpected changes to tyrosine and peripheral neurotransmitter 
metabolism is not clear. At the supraphysiological concentrations observed in AKU, HGA 
could potentially act on other enzymes of neurotransmitter metabolites and alter their 
activity. Alternatively, the changes could relate to an unknown feature of the disease. It is 
important to determine whether the changes observed in peripheral neurotransmitter 
metabolism indicate dysregulated central nervous system (CNS) homeostasis. Recent 
mass spectrometric mouse brain imaging analyses support that in nitisinone-treated AKU, 
CNS metabolic alteration is limited to tyrosine and tyramine (32). Further analyses of CNS 
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tissues and biofluids (CSF) are required to provide a clearer picture of neurotransmitter 
metabolism in untreated AKU. 
The finding that p-hydroxyphenylacetic acid and 4-hydroxybenzaldehyde were increased 
in Hgd-/- mice and further increased on nitisinone is interesting. P-Hydroxyphenylacetic 
acid is generated from gut microbiota and its increase on nitisinone was thought to reflect 
enhanced microbial metabolism due to reduced oxidative stress upon commencement of 
treatment (Davison et al., 2019a). 4-Hydroxybenzaldehyde is a naturally occurring 
metabolite with therapeutic properties in numerous diseases (Kang et al., 2017). 
Benzaldehydes may relate to the proposed benzoquinone intermediates involved in the 
formation of ochronotic pigment from HGA, but the reason for the further increase in 4-
hydroxybenzaldehyde following nitisinone is inconsistent with this and requires 
explanation. 
4.2.2 Alteration to purine metabolism 
In nitisinone-treated AKU the purine metabolite changes previously reported were mainly 
decreased concentrations; 3-ureidoproprionate, adenine and allantoin were decreased in 
human urine, and 3,5-cyclic AMP and xanthosine were decreased in human and mouse 
urine (Norman et al., 2019). The present data indicate a more complex pattern of purine 
alteration in untreated AKU; increased 3,5-cyclic AMP and xanthosine, and decreased 
2,3-cyclic AMP and inosine 5’-monophosphate. 
Purine catabolism is important in the homeostatic response to various states of 
mitochondrial oxidative stress, with shifts occurring to favour breakdown to xanthine and 
uric acid (Kristal et al., 1999; Yao et al., 2010). The increased xanthosine and decreased 
2,3-cyclic AMP and inosine 5’-monophosphate reported here for Hgd-/- mice is consistent 
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with a shift in purine catabolism in response to oxidative conditions induced by HGA and 
ochronosis, as xanthosine is a direct precursor for xanthine and uric acid. Xanthosine is 
increased in urine from rats with other oxidative diseases, including chronic kidney 
disease (Zhang et al., 2015) and diabetes nephropathy, and markedly decreased 
following administration of nephroprotective therapy (Men et al., 2017).  The alteration in 
purine metabolism perhaps most associated with pathology is elevated uric acid, the 
classic example being gout, in which elevated blood uric acid is the direct cause of a 
painful arthropathy.  
4.2.3 Alteration to TCA cycle metabolism 
Decreases in TCA-related metabolites in Hgd-/- is the first indication of perturbed energy 
metabolism in untreated AKU. Decreases in citramalic acid, isocitrate and N-acetyl-L-
glutamic acid were reversed on nitisinone in Hgd-/-, suggesting for the first time that 
nitisinone is at least partially restorative. Malic acid and isocitrate are major intermediates 
of the TCA cycle; the primary energy-producing pathway of the cell. Blood and urine levels 
of TCA metabolites generally reflect overall TCA cycle activity (Hallan et al., 2017). 
Inhibited TCA cycle activity could be due to overall mitochondrial biogenesis, decreased 
expression of genes encoding TCA cycle enzymes or reduced substrate availability; the 
latter seems more likely in AKU, in which HGD deficiency prevents further metabolism of 
HGA to the TCA cycle intermediate fumaric acid. Decreased bioavailability of fumaric acid 
may then explain the decreases observed for other TCA cycle metabolites. Previous 
analyses have investigated serum TCA cycle metabolites in AKU, but these were limited 
to studying the effect of nitisinone. In contrast to the present urinary data, the TCA 
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metabolites succinic acid and α-ketoglutaric acid were decreased in serum from patients 
with AKU following nitisinone (Davison et al., 2019a).  
Decreased urinary citrate (precursor for and structural isomer of isocitrate) is a well-
known risk factor for kidney stone formation. It is possible that the decreased isocitrate 
reported here for Hgd-/- mice is associated with the increased risk of kidney stones in AKU 
(Wolff et al., 2015). In this analysis isocitrate was the closest match obtained for this 
particular entity (RT=1.7 min) based on its AMRT in our database generated from 
standards (RT=1.6 min), but citric acid is also a potential match, with the same accurate 
mass but slightly different database RT (1.9 min). It is important to note that the database 
RTs were obtained from standards analysed in blank matrix, therefore a degree of RT 
shift can be expected in urine matrix due to effects such as pH. Hypocitratururia is 
generally defined as citric acid excretion <320mg (1.67mmol) per day in adults 
(Zuckerman and Assimos, 2009). The present profiling data are semi-quantitative; 
targeted quantitative assays are required to determine exact urinary citric acid 
concentrations in AKU patients and the additional therapeutic value of nitisinone in this 
regard. 
 
5. Conclusions 
In conclusion, we have compared, for the first time, the metabolome-wide profiles of 
untreated AKU (Hgd-/- mice) versus non-AKU (Hgd+/- mice). The data indicate that 
targeted homozygous disruption to the Hgd gene induces previously unknown metabolite 
changes in a complex network of pathways associated with altered tyrosine metabolism. 
Single-gene disorders, such as AKU, therefore present unique windows into metabolism 
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that can uncover associations between metabolite pathways in physiology more 
generally. It was also revealed for the first time that a range of phase I and II metabolic 
processes are recruited for clearance of elevated HGA, which is central to the 
pathological features of AKU. These data have wider, clinically-significant implications 
beyond AKU by showing that phase I and II metabolic processes are recruited for 
detoxification of endogenous metabolites that can accumulate as a consequence of 
inherited metabolic disease. Our findings therefore highlight that it is a fundamental 
misconception to view these ancient, evolved processes solely as mechanisms for drug 
clearance. The wider take-home message is that rare diseases offer unique insights into 
metabolism, and even nature, more generally. As stated by the great physician, William 
Harvey (1578-1657); “nature is nowhere accustomed more openly to display her secret 
mysteries than in cases where she shows traces of her workings apart from the beaten 
path” (Wills, 1847).  
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